Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence, Mechanistic Insights, and Ablation of Atrial Tachycardia Occurring After Pulsed Field Ablation for Atrial Fibrillation: Results From a Large International Registry.

JACC. Clinical electrophysiology·2026
Same author

Posterior mitral isthmus ablation using a balloon-in-basket pulsed-field multielectrode catheter.

HeartRhythm case reports·2026
Same author

Early complications and long-term outcome of patients treated with a Subcutaneous Cardioverter-Defibrillator: temporal trends and clinical implications of the anesthetic strategies adopted at implant.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

The Predictive Value of Impedance for Defibrillation Success After S-ICD Implantation: A Reliable Indicator?

JACC. Clinical electrophysiology·2026
Same author

Outcomes of left atrial appendage closure vs oral anticoagulation after catheter ablation among patients with higher and lower stroke risk: A subanalysis of the OPTION clinical trial.

Heart rhythm·2026
Same author

One-Year Outcomes of the First 1000 Patients Implanted With the Medtronic Micra AV Leadless Pacing System in France: The AV-CESAR Cohort Study.

Circulation. Arrhythmia and electrophysiology·2026

Related Experiment Video

Updated: Jul 18, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

[Arrhythmia-induced dilated cardiomyopathies].

Jean-Paul Bounhoure1, Serge Boveda, Jean-Paul Albenque

  • 1Clinique Pasteur Unité de Rythmologie, Avenue de Lombez, Toulouse 31076.

Bulletin De L'Academie Nationale De Medecine
|January 2, 2007
PubMed
Summary

Arrhythmic cardiomyopathies result from chronic tachycardia, causing reversible heart failure. Treatment focuses on restoring normal heart rhythm, leading to significant recovery.

More Related Videos

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Related Experiment Videos

Last Updated: Jul 18, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Research

Background:

  • Arrhythmic cardiomyopathies are characterized by ventricular dysfunction secondary to prolonged or chronic tachycardia.
  • This condition presents clinically as congestive heart failure, which is reversible upon treating the underlying tachycardia and restoring sinus rhythm.
  • Pacing-induced heart failure models demonstrate profound, reversible ventricular dysfunction and associated neuroendocrine, metabolic, electrophysiological, and anatomic myocardial alterations.

Purpose of the Study:

  • To elucidate the mechanisms and clinical implications of cardiomyopathies induced by chronic tachycardia.
  • To review the diagnostic and therapeutic strategies for managing heart failure secondary to arrhythmias.

Main Methods:

  • Review of existing literature on tachycardia-induced heart failure and pacing models.
  • Analysis of pathophysiological mechanisms including cardiomyocyte dysfunction and excitation-contraction coupling disturbances.
  • Evaluation of treatment modalities aimed at rhythm control and rate management.

Main Results:

  • Heart failure associated with chronic tachycardia is largely reversible with rhythm control, though recovery duration varies.
  • The development of cardiomyopathy is influenced more by heart rate and arrhythmia duration than by arrhythmia type.
  • Multiple complex pathophysiological mechanisms contribute, including cardiomyocyte structural and functional abnormalities.

Conclusions:

  • Restoring and maintaining sinus rhythm, or controlling ventricular rate, are key treatment goals for arrhythmic cardiomyopathies.
  • Radiofrequency ablation is the preferred curative treatment for localized arrhythmogenic substrates.
  • Radiofrequency modification of atrioventricular conduction is the treatment of choice for rate control in chronic atrial fibrillation.